drugset / Trial / NCT06879470
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma.
Timeline
- Start
- 2025-03
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY231 | Cell therapy | — | Intravenous |